MAPT and type 1 diabetes mellitus: Metformin offers neuroprotection by reducing Aß burden in the parietal cortex [184], lowering Aß42 through decreased ß-secretase expression [185], and preventing tau hyperphosphorylation in the cortex and hippocampus from STZ-induced T1D models [184–186].